脾多肽联合布地奈德雾化吸入对COPD急性加重期患者肺功能及动脉血气指标的影响

发布时间：2019-05-22 02:57

【摘要】：目的研究脾多肽联合布地奈德雾化吸入对慢性阻塞性肺疾病急性加重期(AECOPD)患者肺功能及动脉血气指标的影响。方法 AECOPD患者84例随机分组,各42例。对照组予以布地奈德雾化吸入治疗,观察组予以脾多肽+布地奈德雾化吸入治疗。比较两组临床疗效,治疗前后用力肺活量(FVC)、1 s用力呼气容积(FEV1)、FEV1/FVC及动脉二氧化碳分压(PaCO_2)、动脉血氧分压(PaO_2)]变化。结果观察组临床治疗总有效率92.86%高于对照组71.43%(P0.05);治疗后观察组FVC、FEV1、FEV1/FVC高于对照组(P0.05);PaCO_2低于对照组、Pa O_2高于对照组(P0.05)。结论联合脾多肽和布地奈德雾化吸入用于AECOPD患者,可改善肺功能及动脉血气指标,疗效显著。
[Abstract]:Objective to study the effect of spleen polypeptide combined with budesonide atomization inhalation on pulmonary function and arterial blood gas in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods 84 patients with AECOPD were randomly divided into two groups, 42 patients each. The control group was treated with budesonide atomization inhalation, and the observation group was treated with spleen polypeptide budesonide atomization inhalation. The changes of forced vital capacity (FVC), 1 s forced breath volume (FEV1), FEV1/FVC, arterial partial pressure of carbon dioxide (PaCO_2) and arterial partial pressure of oxygen (PaO_2) were compared between the two groups before and after treatment. Results the total effective rate of clinical treatment in the observation group was 92.86%, which was higher than that in the control group (P 0.05), and the FVC,FEV1,FEV1/FVC in the observation group was higher than that in the control group after treatment (P 0.05). PaCO_2 was lower than that of the control group, and Pa O 鈮，

本文编号：2482617